Showing results (301-310 of 650) with videos related to
Sort By:
Pageof 65
Nature Cancer|August 3, 2023
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissuesPengle Yao, Peng Xiao, Zongyao Huang, et al.Nature Cancer|August 3, 2023
Cancer cell plasticity during tumor progression, metastasis and response to therapyAndrea Pérez-González, Kevin Bévant, Cédric BlanpainNature Cancer|April 15, 2026
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapyYingqin Li, Dongxue Wang, Chunxian Ou, et al.Nature Cancer|April 19, 2024
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myelomaMichael Rade, Nora Grieb, Ronald Weiss, et al.Nature Cancer|April 18, 2024
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumorsSanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, et al.Nature Cancer|October 31, 2023
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy targetKamal Mandal, Gianina Wicaksono, Clinton Yu, et al.Nature Cancer|August 31, 2023
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivationJennifer Derrien, Sarah Gastineau, Antoine Frigout, et al.Nature Cancer|August 28, 2023
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerJessica L Chitty, Michelle Yam, Lara Perryman, et al.Nature Cancer|June 4, 2026
Bacterial engineering for cancer therapyNoah Chen, Zaofeng Yang, Nicholas ArpaiaNature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.Pageof 65